GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » EPS (Diluted)

Biotechnology Assets (XMAD:BST) EPS (Diluted) : €0.03 (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets EPS (Diluted)?

Biotechnology Assets's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.03.

Biotechnology Assets's EPS (Basic) for the six months ended in Dec. 2023 was €-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.03.

Biotechnology Assets's EPS without NRI for the six months ended in Dec. 2023 was €-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Biotechnology Assets's highest 3-Year average EPS without NRI Growth Rate was 73.90% per year. The lowest was -99.70% per year. And the median was 16.30% per year.


Biotechnology Assets EPS (Diluted) Historical Data

The historical data trend for Biotechnology Assets's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets EPS (Diluted) Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.22 -0.07 -0.04 0.03

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.01 0.05 -0.02

Competitive Comparison of Biotechnology Assets's EPS (Diluted)

For the Biotechnology subindustry, Biotechnology Assets's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotechnology Assets's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's PE Ratio falls into.



Biotechnology Assets EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Biotechnology Assets's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1.574-0)/57.726
=0.03

Biotechnology Assets's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.38-0)/57.726
=-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotechnology Assets  (XMAD:BST) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biotechnology Assets EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotechnology Assets (XMAD:BST) Business Description

Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.